RJFSA
CYTK icon

Raymond James Financial Services Advisors’s Cytokinetics CYTK Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,204
Closed -$298K – 2872
2019
Q3 		$298K Sell
26,204
-445
-2% -$5.59K ﹤0.01% 2252
2019
Q2 		$300K Buy
+26,649
New +$257K ﹤0.01% 2276

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Raymond James Financial Services Advisors's CYTK Position: Q4 2019 in Review

Raymond James Financial Services Advisors sold out of Cytokinetics (CYTK) in Q4 2019, closing a stake of 26,204 shares — an estimated $298K sold.

Raymond James Financial Services Advisors first reported a position in CYTK in Q2 2019 and held it in 2 quarters. The position peaked at $300K in Q2 2019. 142 funds tracked by Wall St. Rank hold CYTK as of Q4 2019.

  • Raymond James Financial Services Advisors reported no remaining Cytokinetics position as of Q4 2019 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 26,204 Cytokinetics shares in Q4 2019, an estimated $298K.
  • Raymond James Financial Services Advisors first reported a position in Cytokinetics in Q2 2019 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Cytokinetics position peaked at $300K in Q2 2019.
  • 142 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.